Caplin Point Laboratories Ltd has begun commercial production at its newly constructed injectable plant to cater to developed and emerging markets. Caplin Point has informed BSE that the company’s state-of-the-art injectable plant near Gummidipoondi, Tamil Nadu, to cater regulated markets USA, EU, Brazil, South Africa, etc, has commenced its commercial production on March 27, 2014. With this, the company will now be able to export these products to semi-regulated and non-regulated markets.
The company has now initiated the process of submitting required documents for obtaining approval from regulatory bodies such as UK MHRA, ANVISA, BRAZIL, US FDA, EUGMP, etc which would enable export of injectables in various dosage forms to the regulated markets besides offering contract manufacturing for export to these markets.
The company has now initiated the process of submitting required documents for obtaining approval from regulatory bodies such as UK MHRA, ANVISA, BRAZIL, US FDA, EUGMP, etc which would enable export of injectables in various dosage forms to the regulated markets besides offering contract manufacturing for export to these markets.